Syndax Pharmaceuticals Inc Chief Financial Officer Aaron Ondrey filed a Form 4 on November 12, 2026, disclosing the acquisition of 270,000 stock options on November 9, 2026.

Key Highlights

  • Reporting person: Aaron Ondrey, Chief Financial Officer of Syndax Pharmaceuticals Inc (NASDAQ:SNDX)
  • Transaction date: November 9, 2026
  • Security acquired: Stock Option (Right to buy) covering 270,000 shares of Common Stock
  • Exercise price: $9.55 per share
  • Expiration date: November 9, 2036
  • Post-transaction derivative holdings: 270,000 options held directly, with 0 disposed

Aaron Ondrey's Stock Option Grant at Syndax Pharmaceuticals

According to the filing, Aaron Ondrey, serving as Chief Financial Officer of Syndax Pharmaceuticals Inc, acquired a stock option to purchase 270,000 shares of Common Stock at an exercise price of $9.55 per share. The transaction was recorded with a transaction code of "A" (acquired) and carries an expiration date of November 9, 2036. The option is listed as a derivative security under Table II of the Form 4, held directly by the reporting person.

The filing includes an explanation of the vesting schedule. According to the response footnote, "Twenty-five percent (25%) of the total number of shares will vest on the one (1) year anniversary of the Vesting Commencement Date and one forty-eighth (1/48th) of the shares of Common Stock subject to the Option shall vest monthly thereafter during the recipient's continued service as an employee, consultant, director or officer of the Company over the following thirty-six (36) months, until all of the shares subject to the Option are fully vested." This results in a four-year total vesting period.

The form was filed by one reporting person and signed by Michael A. Metzger as Attorney-in-Fact on November 12, 2026. No shares of non-derivative (common) stock were reported as acquired or disposed of in Table I of this filing. The Form 4 does not indicate that the transaction was made pursuant to a Rule 10b5-1 trading plan, as the corresponding checkbox was not checked.

What Was Disclosed

Syndax Pharmaceuticals CFO Aaron Ondrey disclosed the acquisition of 270,000 stock options with a $9.55 exercise price and a ten-year term expiring November 9, 2036, subject to a four-year vesting schedule beginning with a one-year cliff.